Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

A safety-modified SV40 Tag developed for human cancer immunotherapy

Authors Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al

Published 8 January 2008 Volume 2008:2 Pages 17—24

Stephanie S Tseng-Rogenski1, Mohamed S Arredouani2, June F Escara-Wilke1, Yilin C Neeley1, Michael J Imperiale3, Martin G Sanda1,2

1Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, USA; 2Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 3Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, USA

Abstract: Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.
Keywords: modified SV-40 T antigen, recombinant vaccinia, cancer immunotherapy

Download Article [PDF] 

Readers of this article also read:

Oral and pharyngeal bolus transit in patients with chronic obstructive pulmonary disease

Cassiani RA, Santos CM, Baddini-Martinez J, Dantas RO

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:489-496

Published Date: 5 March 2015

Effects of Wharton's jelly-derived mesenchymal stem cells on neonatal neutrophils

Khan I, Zhang L, Mohammed M, Archer FE, Abukharmah J, Yuan Z, Rizvi SS, Melek MG, Rabson AB, Shi Y, Weinberger B, Vetrano AM

Journal of Inflammation Research 2015, 8:1-8

Published Date: 31 December 2014

Glaucomatous optic nerve head alterations in patients with chronic heart failure

Meira-Freitas D, Melo Jr LAS, Almeida-Freitas DB, Paranhos Jr A

Clinical Ophthalmology 2012, 6:623-629

Published Date: 27 April 2012

PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses

Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T, Minev B

International Journal of Nanomedicine 2012, 7:1475-1487

Published Date: 15 March 2012

Survival of patients with ovarian cancer in central and northern Denmark, 1998–2009

Grann AF, Nørgaard M, Blaakær J, Søgaard-Andersen E, Jacobsen JB

Clinical Epidemiology 2011, 3:59-64

Published Date: 21 July 2011

Enhanced effect and mechanism of water-in-oil microemulsion as an oral delivery system of hydroxysafflor yellow A

Qi J, Zhuang J, Wu W, Lu Y, Song Y, Zhang Z, Jia J, Ping Q

International Journal of Nanomedicine 2011, 6:985-991

Published Date: 10 May 2011

Drug design with Cdc7 kinase: a potential novel cancer therapy target

Masaaki Sawa, Hisao Masai

Drug Design, Development and Therapy 2008, 2:255-264

Published Date: 18 November 2008

Therapy of autoimmune bullous diseases

Diya F Mutasim

Therapeutics and Clinical Risk Management 2007, 3:29-40

Published Date: 15 March 2007